Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have expanded their partnership to include commercial manufacturing support for Taysha's investigational gene therapy TSHA-102 targeting Rett syndrome. The agreement ensures long-term commercial manufacturing capacity at Catalent's FDA-licensed facility, supporting a potential U.S. launch pending FDA approval. Thi…